Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A

Journal of Medical Virology

Volumn 89, Issue 2, 2017, Pages 267-275

  Tsunematsu, Seiji ^a   Suda, Goki ^a   Yamasaki, Kazushi ^a   Kimura, Megumi ^a   Izumi, Takaaki ^a   Umemura, Machiko ^a   Ito, Jun ^a   Sato, Fumiyuki ^a   Nakai, Masato ^a   Sho, Takuya ^a   Morikawa, Kenichi ^a   Ogawa, Koji ^a   Tanaka, Yasuhito ^b   Watashi, Koichi ^c   Wakita, Takaji ^c   Sakamoto, Naoya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

biopsy; cytokine signaling 3; hepatitis B virus X protein; interferon signaling; protein phosphatase 2A

Indexed keywords

ALPHA INTERFERON; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; PHOSPHOPROTEIN PHOSPHATASE 2A; SUPPRESSOR OF CYTOKINE SIGNALING 3; PHOSPHOPROTEIN PHOSPHATASE 2; SOCS3 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENE TRANSFER; HEPATITIS B; HUMAN; HUMAN CELL; OPEN READING FRAME; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; HEP-G2 CELL LINE; HEPATITIS B VIRUS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; METABOLISM; PHYSIOLOGY;

HEP G2 CELLS; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; INTERFERON-ALPHA; PROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; TRANS-ACTIVATORS; UP-REGULATION;

EID: 84994676859     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24643     Document Type: Article

References (35)

1. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet IS, Norton RS, Nicola NA. 2012. Suppression of cytokine signaling by SOCS3: Characterization of the mode of inhibition and the basis of its specificity. Immunity 36:239–250.
2. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol 13:48–64.
3. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, Yuan Z. 2013. Hepatitis B virus polymerase impairs interferon-alpha-induced STA T activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology 57:470–482.
4. Christen V, Treves S, Duong FH, Heim MH. 2007. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 46:558–565.
5. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. 2007. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 81:159–165.
6. Darnell JE, Jr., Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415–1421.
7. Janssens V, Goris J. 2001. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417–439.
8. Kim K, Kim KH, Cheong J. 2010. Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3. PLoS ONE 5:e8649.
9. Koeberlein B, zur Hausen A, Bektas N, Zentgraf H, Chin R, Nguyen LT, Kandolf R, Torresi J, Bock CT. 2010. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res 148:51–59.
10. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733–1745.
11. Levy DE, Darnell JE, Jr. 2002. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662.
12. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. 1998. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 95:10626–10631.
13. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N. 2015. A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol Ther 16:1453–1461.
14. Mahoney FJ. 1999. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12:351–366.
15. Ni M, Lee AS. 2007. ER chaperones in mammalian development and human diseases. FEBS Lett 581:3641–3651.
16. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. 2007. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev 21:2788–2803.
17. Payelle-Brogard B, Pellegrini S. 2010. Biochemical monitoring of the early endocytic traffic of the type I interferon receptor. J Interferon Cytokine Res 30:89–98.
18. Rosmorduc O, Sirma H, Soussan P, Gordien E, Lebon P, Horisberger M, Bréchot C, Kremsdorf D. 1999. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 80:1253–1262.
19. Seeger C, Mason W. 2000. Hepatitis B virus biology. Microbiol Mol Biol Rev 64:51–68.
20. Sells MA, Chen M-L, Acs G. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84:1005–1009.
21. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921.
22. Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Watanabe M. 2010. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 407:80–90.
23. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. 2006. Influence of hepatitis B virus genotypes on the intra-and extracellular expression of viral DNA and antigens. Hepatology 44:915–924.
24. Takaoka M, Harada H, Deramaudt TB, Oyama K, Andl CD, Johnstone CN, Rhoades B, Enders GH, Opitz OG, Nakagawa H. 2004. Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction. Oncogene 23:6760–6768.
25. Takaoka M, Kim SH, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H. 2007. IGFBP-3 regulates esophageal tumor growth through IGFDependent and independent mechanisms. Cancer Biol Ther 6:534–540.
26. Tang H, Oishi N, Kaneko S, Murakami S. 2006. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 97:977–983.
27. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. 2002. Regulation of Jak2 through the Ubiquitin-Proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22:3316–3326.
28. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. 2006. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55:529–535.
29. Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. 2011. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 26:1757–1764.
30. Waris G, Huh KW, Siddiqui A. 2001. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol Cell Biol 21:7721–7730.
31. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Yang X, Wang Y, Wen C, Wu Q, Shi W, Zhong H. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185:1158–1168.
32. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312–323.
33. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. 2009. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49:1032–1040.
34. Yu H, Jove R. 2004. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4:97–105.
35. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91:2080–2090.